1375 related articles for article (PubMed ID: 29428165)
1. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.
Liu N; Chen NY; Cui RX; Li WF; Li Y; Wei RR; Zhang MY; Sun Y; Huang BJ; Chen M; He QM; Jiang N; Chen L; Cho WC; Yun JP; Zeng J; Liu LZ; Li L; Guo Y; Wang HY; Ma J
Lancet Oncol; 2012 Jun; 13(6):633-41. PubMed ID: 22560814
[TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a magnetic resonance imaging-based model for the prediction of distant metastasis before initial treatment of nasopharyngeal carcinoma: A retrospective cohort study.
Zhang L; Dong D; Li H; Tian J; Ouyang F; Mo X; Zhang B; Luo X; Lian Z; Pei S; Dong Y; Huang W; Liang C; Liu J; Zhang S
EBioMedicine; 2019 Feb; 40():327-335. PubMed ID: 30642750
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment MRI radiomics analysis allows for reliable prediction of local recurrence in non-metastatic T4 nasopharyngeal carcinoma.
Zhang LL; Huang MY; Li Y; Liang JH; Gao TS; Deng B; Yao JJ; Lin L; Chen FP; Huang XD; Kou J; Li CF; Xie CM; Lu Y; Sun Y
EBioMedicine; 2019 Apr; 42():270-280. PubMed ID: 30928358
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ
Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
[TBL] [Abstract][Full Text] [Related]
9. Establishment and validation of two nomograms to predict the benefit of concurrent chemotherapy in stage II-IVa nasopharyngeal carcinoma patients with different risk factors: Analysis based on a large cohort.
Sun XS; Xiao BB; Lin C; Liu SL; Chen QY; Tang LQ; Mai HQ
Cancer Med; 2020 Mar; 9(5):1661-1670. PubMed ID: 31925942
[TBL] [Abstract][Full Text] [Related]
10. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area.
Yao JJ; Lin L; Gao TS; Zhang WJ; Lawrence WR; Ma J; Sun Y
Cancer Res Treat; 2021 Jul; 53(3):657-670. PubMed ID: 33285052
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of primary gross tumor volume and standardized uptake value of
Jin YN; Yao JJ; Wang SY; Zhang WJ; Zhou GQ; Zhang F; Cheng ZB; Ma J; Mo HY; Sun Y
Tumour Biol; 2017 Jul; 39(7):1010428317717843. PubMed ID: 28671052
[TBL] [Abstract][Full Text] [Related]
14. A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma.
Liang YL; Zhang Y; Tan XR; Qiao H; Liu SR; Tang LL; Mao YP; Chen L; Li WF; Zhou GQ; Zhao Y; Li JY; Li Q; Huang SY; Gong S; Zheng ZQ; Li ZX; Sun Y; Jiang W; Ma J; Li YQ; Liu N
Nat Commun; 2022 May; 13(1):2996. PubMed ID: 35637194
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
16. A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
Lei Y; Li YQ; Jiang W; Hong XH; Ge WX; Zhang Y; Hu WH; Wang YQ; Liang YL; Li JY; Cho WCS; Yun JP; Zeng J; Chen JW; Liu LZ; Li L; Chen L; Xie FY; Li WF; Mao YP; Liu X; Chen YP; Tang LL; Sun Y; Liu N; Ma J
J Natl Cancer Inst; 2021 Apr; 113(4):471-480. PubMed ID: 33094348
[TBL] [Abstract][Full Text] [Related]
17. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
18. Association of Intratumoral Microbiota With Prognosis in Patients With Nasopharyngeal Carcinoma From 2 Hospitals in China.
Qiao H; Tan XR; Li H; Li JY; Chen XZ; Li YQ; Li WF; Tang LL; Zhou GQ; Zhang Y; Liang YL; He QM; Zhao Y; Huang SY; Gong S; Li Q; Ye ML; Chen KL; Sun Y; Ma J; Liu N
JAMA Oncol; 2022 Sep; 8(9):1301-1309. PubMed ID: 35834269
[TBL] [Abstract][Full Text] [Related]
19. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma.
Liu N; Cui RX; Sun Y; Guo R; Mao YP; Tang LL; Jiang W; Liu X; Cheng YK; He QM; Cho WC; Liu LZ; Li L; Ma J
Int J Cancer; 2014 Mar; 134(6):1359-68. PubMed ID: 23999999
[TBL] [Abstract][Full Text] [Related]
20. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Chen YP; Liu X; Zhou Q; Yang KY; Jin F; Zhu XD; Shi M; Hu GQ; Hu WH; Sun Y; Wu HF; Wu H; Lin Q; Wang H; Tian Y; Zhang N; Wang XC; Shen LF; Liu ZZ; Huang J; Luo XL; Li L; Zang J; Mei Q; Zheng BM; Yue D; Xu J; Wu SG; Shi YX; Mao YP; Chen L; Li WF; Zhou GQ; Sun R; Guo R; Zhang Y; Xu C; Lv JW; Guo Y; Feng HX; Tang LL; Xie FY; Sun Y; Ma J
Lancet; 2021 Jul; 398(10297):303-313. PubMed ID: 34111416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
